Meanwhile Robert we have another no news day on the MOS front. Based on what King said, I firmly believe every day the MOS numbers are growing in both the front line NSCLC and Pancreatic cancer trials. Every day without an announcement will IMO bring us closer to the things we longs want, i.e. FDA approvals, share price upward movement, partnering deals or a buyout.
In our case the longer we wait, the better our outcomes. So, I wouldn't put too much stock in the opinions expressed here or elsewhere. If the market doesn't understand what Peregrine is achieving, then we may be able to pick up more shares cheaply. If we dip low enough, I'll add.
Paul
Market Data 
Markets 
